ID | 118639 |
Title Alternative | A multicenter survey for submacular hemorrhage
|
Author |
Kimura, Takeshi
Hyogo College of Medicine
Araki, Takashi
Hyogo College of Medicine
Yasukawa, Tsutomu
Nagoya City University
Kato, Aki
Nagoya City University
Kuwayama, Soichiro
Nagoya City University
Kinoshita, Takamasa
Sapporo City General Hospital
Okamoto, Fumiki
University of Tsukuba
Murakami, Tomoya
University of Tsukuba
Mitamura, Yoshinori
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Sakamoto, Taiji
Kagoshima University
Terasaki, Hiroto
Kagoshima University
Kusuhara, Sentaro
Kobe University
Miki, Akiko
Kobe University
Takamura, Yoshihiro
Fukui University
Kondo, Mineo
Mie University
Matsubara, Hisashi
Mie University
Ueda, Tetsuo
Nara Medical University
Tsujinaka, Hiroki
Nara Medical University
Gomi, Fumi
Hyogo College of Medicine
|
Content Type |
Journal Article
|
Description | Purpose
To evaluate the clinical characteristics, treatment trends, and visual prognosis of submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD) and retinal arterial macroaneurysm (RAM). Methods This retrospective study enrolled 187 Japanese patients with SMH at 10 institutions from 2015 to 2018. Medical records including SMH etiology, best-corrected visual acuity (BCVA), fundus photographs, optical coherence tomography images, and selected treatments were analyzed. Results Major causes of SMH were typical nAMD (tnAMD) (18%), polypoidal choroidal vasculopathy (PCV) (50%) and RAM (29%). Age, male/female ratio, baseline BCVA, central retinal thickness, and involved retinal layers were significantly different between etiologies (all P<0.0001). Treatment with anti-vascular endothelial growth factor drugs with and without intravitreal gas injection was chosen for half of eyes in the tnAMD and PCV groups, whereas vitrectomy was performed in 83.7% of eyes with RAM. The final BCVA improved significantly from baseline in the PCV and RAM groups (P = 0.0009, P<0.0001) and final BCVA was significantly better in the PCV group at a level similar to the other groups (P = 0.0007, P = 0.0008). BCVA improvement from baseline was significantly greater in the RAM group compared with the tnAMD (P = 0.0152) and PCV (P = 0.017) groups. Multivariate analysis revealed better final BCVA was significantly associated with younger age (P = 0.0054), better baseline BCVA (P = 0.0021), RAM subtype (P = 0.0446), and no tnAMD (P = 0.001). Conclusions The characteristics of, and treatment strategy for, SMH were different between the underlying diseases. Anti-vascular endothelial growth factor treatment with or without expansile gas was mainly chosen for SMH in tnAMD and PCV, whereas vitrectomy with gas was the most common treatment for RAM, and the higher rate for vitrectomy might result in the greater BCVA improvement in the RAM group than in the other groups. Final BCVA was better in PCV, RAM, and tnAMD, in that order, because patients with PCV were younger and had better baseline BCVA. |
Journal Title |
PLOS ONE
|
ISSN | 19326203
|
Publisher | PLOS
|
Volume | 17
|
Issue | 9
|
Start Page | e0274508
|
Published Date | 2022-09-29
|
Rights | This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
University Hospital
Medical Sciences
|